相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors
Lei Ye et al.
ENDOCRINE REVIEWS (2010)
Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
Maria E. Cabanillas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Elaine T. Lam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
Hung Huynh et al.
JOURNAL OF HEPATOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Targeting the RET Pathway in Thyroid Cancer
Samuel A. Wells et al.
CLINICAL CANCER RESEARCH (2009)
Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer
Ning Jin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers
Steven I. Sherman
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer
Shu Yang et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Young-Kwang Yoon et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Richard T. Kloos et al.
THYROID (2009)
Targeting protein translation in human non-small cell lung cancer via combined MEK and mammalian target of rapamycin suppression
Marie-Emmanuelle Legrier et al.
CANCER RESEARCH (2007)
Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer
Lin Zhang et al.
CLINICAL CANCER RESEARCH (2007)
BAY 43-9006 inhibition of oncogenic RET mutants
F Carlomagno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Restraining PI3K: mTOR signalling goes back to the membrane
LS Harrington et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/akt and raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodericient mice
B Bedogni et al.
CANCER RESEARCH (2004)
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies
OJ Shah et al.
CURRENT BIOLOGY (2004)
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
LS Harrington et al.
JOURNAL OF CELL BIOLOGY (2004)
分享论文
